Otsuka Pharmaceutical said on January 6 that it has filed a new drug application in Japan for its novel antipsychotic drug brexpiprazole for the treatment of schizophrenia. Brexpiprazole is being developed jointly with Danish partner Lundbeck. It is a serotonin-dopamine…
To read the full story
Related Article
- Rexulti OK’ed for Schizophrenia Maintenance Therapy in US
September 27, 2016
- US FDA Approves Novel Antipsychotic Agent Rexulti: Otsuka, Lundbeck
July 14, 2015
BUSINESS
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
- Torii to Transfer Locoid MA in Japan to Cheplapharm
July 24, 2026
- Japan Vaccine Market Seen Flat in FY2026; Efluelda Delay Clouds Outlook
July 24, 2026
- Nipro Recalls Febuxostat after Finding Expired API Use at Another Plant
July 23, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





